Radiopharmaceuticals
Accelerating radiopharmaceutical development in oncology
Receive your quote directly from the manufacturer.
- Radiopharmaceuticals are a class of targeted therapeutics that deliver radioactive isotopes directly to cancer cells. These agents combine a biologically active targeting molecule — such as a peptide, antibody, or small molecule — with a radioisotope that emits ionizing radiation. Once bound to its target, the radiopharmaceutical delivers localized radiation to kill tumor cells with high precision while minimizing damage to surrounding healthy tissue.
- Radiopharmaceuticals are increasingly being used in both diagnostic imaging (e.g., PET, SPECT) and therapeutic applications (e.g., targeted alpha and beta therapies), making them a powerful tool in precision oncology.
A strategic alliance for innovation in radiopharmaceuticals
Together, Crown Bioscience and Medicines Discovery Catapult (MDC) are building an integrated ecosystem for radiopharmaceutical innovation, bridging discovery, imaging, pharmacology, and translational models to support oncology drug developers.
Radiopharmaceutical – The evolving role of radiation in targeted cancer therapy
Radiopharmaceutical therapy (RPT) offers a unique way to selectively target and destroy cancer cells using radioactive isotopes. The clinical success of therapies like Pluvicto™ and Lutathera® demonstrate the promise of RPT, particularly in advanced or resistant tumors. Furthermore, preclinical evaluation using appropriate models and imaging platforms plays a pivotal role in ensuring the translational success of these innovative therapies.
As research and technology continue to advance, the field of radiopharmaceuticals holds great potential to revolutionize cancer treatment. Discover why this field is gaining traction, and how by harnessing the power of radiation and precision medicine, RPT offers new hope for more effective cancer therapies.
